Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

A Phase I Multiple Ascending Dose Study of BMS-754807 in Subjects With Advanced or Metastatic Solid Tumors

This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 for Phase 2 studies

Inclusion Criteria:

• Subjects with advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate
• ECOG performance status 0-1
• at least 4 weeks between surgery or last dose prior anti-cancer therapy

Exclusion Criteria:

• symptomatic brain metastases
• any disorder or dysregulation of glucose homeostasis {e.g. diabetes)
• uncontrolled or significant cardiovascular disease
• inadequate bone marrow, liver or kidney function